Camoteskimab

Camoteskimab (AVTX-007) is an anti-IL-18 monoclonal antibody with fully humanized, high-affinity. Camoteskimab specifically binds IL-18 and blocks the interaction of IL-18 with its receptor. Camoteskimab is promising for research of cardiovascular diseases and autoinflammatory diseases, including adult-onset Still’s disease (AOSD) and multiple myeloma[1][2][3][4][5].

Product Specifications

CAS Number

[2492472-82-7]

Product Name Alternative

AVTX-007; CERC-007; MEDI 2338

UNSPSC

12352203

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/camoteskimab.html

Purity

99.0

Solubility

10 mM in DMSO

Smiles

[Camoteskimab]

Molecular Weight

(146.34 kDa)

References & Citations

[1]Paola Galozzi, et al. Progress in Biological Therapies for Adult-Onset Still's Disease. Biologics. 2022 Apr 21;16:21-34. |[2]Brennan S, et al. Genetically Predicted IL-18 Inhibition and Risk of Cardiovascular Events: A Mendelian Randomization Study[J]. medRxiv, 2024: 2024.07. 01.24309808.|[3]Bindoli S, et al. Adult-Onset Still's Disease (AOSD) : Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options. Drugs. 2024 Mar;84 (3) :257-274.|[4]Macovei LA, et al. Adult-Onset Still's Disease-A Complex Disease, a Challenging Treatment. Int J Mol Sci. 2022 Oct 24;23 (21) :12810.|[5]Galozzi P, et al. Progress in Biological Therapies for Adult-Onset Still's Disease. Biologics. 2022 Apr 21;16:21-34.